Kailera Therapeutics secured a $600 million Series B to advance its dual‑targeting obesity program into global Phase 3 testing. The Bain Capital‑led round will fund pivotal development of KAI‑9531, a weekly injectable that targets the same receptors as existing GLP‑1/GIP therapies, plus additional metabolic programs in the company’s pipeline. Kailera plans to use the proceeds to initiate international registrational trials and scale manufacturing and regulatory activities. The financing — one of the largest private biotech rounds of the year — signals continued investor conviction in obesity therapeutics despite growing payer scrutiny and market competition.